Corneal Endothelial Dystrophy Market
DelveInsight's "Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Corneal Endothelial Dystrophy, historical and forecasted epidemiology as well as the Corneal Endothelial Dystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Corneal Endothelial Dystrophy market report provides current treatment practices, emerging drugs, Corneal Endothelial Dystrophy market share of the individual therapies, current and forecasted Corneal Endothelial Dystrophy market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Corneal Endothelial Dystrophy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Corneal Endothelial Dystrophy market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Corneal Endothelial Dystrophy Disease Understanding and Treatment Algorithm
Corneal dystrophies constitute a family of uncommon genetic eye disorders, characterized by the gradual and sometimes progressive buildup of abnormal substances within the clear and transparent outer layer of the eye, known as the cornea. These disorders encompass a spectrum of conditions that can lead to varying degrees of visual impairment, making them a significant area of concern in ophthalmology. While the underlying genetic causes of corneal dystrophies are diverse, they share the common trait of affecting the cornea's structural integrity and functionality, underscoring the need for advanced research and therapeutic interventions to address these complex eye conditions.
There are more than 20 different types of corneal dystrophies, which are generally grouped into three categories:
- Anterior or superficial corneal dystrophies affect the outermost layers of the cornea, i.e., the epithelium and Bowman’s membrane.
- Stromal corneal dystrophies affect the stroma, which is the middle and thickest layer of the cornea.
- Posterior corneal dystrophies affect the innermost parts of the cornea i.e., the endothelium and the Descemet membrane, and subtypes include Congenital Hereditary Endothelial Corneal Dystrophy, Fuchs Endothelial Corneal Dystrophy, Posterior Polymorphous Corneal Dystrophy, and Schnyder Crystalline Corneal Dystrophy. The most common posterior corneal dystrophy is Fuchs’ dystrophy (FED).
Most cases of corneal dystrophy are inherited as an autosomal dominant trait with variable expressivity. Posterior polymorphous forms of corneal dystrophy have autosomal dominance inheritance. Fuchs dystrophy may have autosomal dominant inheritance in some cases; in others, it may occur spontaneously for no apparent reason (sporadic). Congenital hereditary corneal dystrophy type II has autosomal recessive inheritance.
Corneal Endothelial Dystrophy Epidemiology
The Corneal Endothelial Dystrophy epidemiology section provides insights about the historical and current Corneal Endothelial Dystrophy patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Corneal Endothelial Dystrophy market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Corneal Endothelial Dystrophy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
Key Findings
-
A 2020 study titled “Fuchs Endothelial Dystrophy (FED)” by Moshirfar et al., suggested that FED has a higher prevalence in Europe compared to other areas of the world and Asians show lower rates of FED. People older than 40 years old and women have a higher risk of developing FED, and it has been reported to have a female-to-male ratio of 2.5:1 to 3:1. There is a rare early-onset form of FED that presents in the first decade of life and has a 1 to 1 female to male ratio.
-
As per the data published in the American Academy of Ophthalmology, in 2020, the exact prevalence of Posterior Polymorphous Corneal Dystrophy (PPMD, PPCD) is not known, studies of the prevalence of corneal dystrophies in the US estimate that 60% of congenital corneal dystrophies have endothelial involvement. PPMD usually presents in early childhood or adolescence as clouding of the stroma that may cause blurred vision. Ocular diseases correlated with PPMD include secondary glaucoma and keratoconus.
Country Wise- Corneal Endothelial Dystrophy Epidemiology
The epidemiology segment also provides the Corneal Endothelial Dystrophy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Report Covers the Corneal Endothelial Dystrophy Epidemiology Segmented as -
- Prevalent Population of Corneal Dystrophy
- Prevalent Population of Corneal Endothelial Dystrophy
- Diagnosed and Treatable Cases of Corneal Endothelial Dystrophy
- Type-specific Prevalent Population of Corneal Endothelial Dystrophy
Corneal Endothelial Dystrophy Drug Chapters
The drug chapter segment of the Corneal Endothelial Dystrophy report encloses the detailed analysis of Corneal Endothelial Dystrophy marketed drugs and late-stage (Phase-III and Phase-II) Corneal Endothelial Dystrophy pipeline drugs. It also helps to understand the Corneal Endothelial Dystrophy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Corneal Endothelial Dystrophy Marketed Drugs
The report provides the details of the marketed products/off-label treatments available for Corneal Endothelial Dystrophy treatment.
Corneal Endothelial Dystrophy Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Corneal Endothelial Dystrophy treatment.
Corneal Endothelial Dystrophy Market Outlook
The Corneal Endothelial Dystrophy market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Corneal Endothelial Dystrophy market trends by analyzing the impact of current Corneal Endothelial Dystrophy therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Corneal Endothelial Dystrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Corneal Endothelial Dystrophy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Corneal Endothelial Dystrophy market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Findings
This section includes a glimpse of the Corneal Endothelial Dystrophy market in 7MM.
The United States Market Outlook
This section provides the total Corneal Endothelial Dystrophy market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Corneal Endothelial Dystrophy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Corneal Endothelial Dystrophy market size and market size by therapies in Japan is also mentioned.
Corneal Endothelial Dystrophy Drugs Uptake
This section focuses on the rate of uptake of the potential Corneal Endothelial Dystrophy drugs recently launched in the Corneal Endothelial Dystrophy market or expected to get launched in the market during the study period 2019-2032. The analysis covers Corneal Endothelial Dystrophy market uptake by drugs; patient uptake by therapies; and sales of each drug.
Corneal Endothelial Dystrophy Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Corneal Endothelial Dystrophy market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Corneal Endothelial Dystrophy Pipeline Development Activities
The Corneal Endothelial Dystrophy report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Corneal Endothelial Dystrophy key players involved in developing targeted therapeutics.
Pipeline Development Activities
The Corneal Endothelial Dystrophy report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Corneal Endothelial Dystrophy emerging therapies.
Corneal Endothelial Dystrophy Market Dynamics and Key Companies in the Domain
The landscape of the Corneal Endothelial Dystrophy market is expected to transform in the near future, driven by significant advancements in research and development initiatives. As the pharmaceutical giants delve deeper into understanding the intricacies of Corneal Endothelial Dystrophy, novel therapeutic approaches and potential breakthroughs are anticipated. These developments hold the promise of offering enhanced treatment options and improved outcomes for individuals afflicted by this challenging eye disorder, ultimately reshaping the market's dynamics.
Some of the key players such as Aerie Pharmaceuticals, Kowa Pharmaceuticals, Trefoil Therapeutics, Emmecell, Surrozen, Price Vision Group, and several others are actively workign in the Corneal Endothelial Dystrophy therapeutics market.
Reimbursement Scenario in Corneal Endothelial Dystrophy
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views on Corneal Endothelial Dystrophy Market
To keep up with current Corneal Endothelial Dystrophy market trends, we take KOLs and SMEs ' opinion working in the Corneal Endothelial Dystrophy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Corneal Endothelial Dystrophy market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Corneal Endothelial Dystrophy Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Corneal Endothelial Dystrophy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Corneal Endothelial Dystrophy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Corneal Endothelial Dystrophy epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Corneal Endothelial Dystrophy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Corneal Endothelial Dystrophy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Corneal Endothelial Dystrophy market
Report Highlights
- In the coming years, the Corneal Endothelial Dystrophy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Corneal Endothelial Dystrophy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Corneal Endothelial Dystrophy. The launch of emerging therapies will significantly impact the Corneal Endothelial Dystrophy market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Corneal Endothelial Dystrophy
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Corneal Endothelial Dystrophy Report Insights
- Corneal Endothelial Dystrophy Patient Population
- Therapeutic Approaches
- Corneal Endothelial Dystrophy Pipeline Analysis
- Corneal Endothelial Dystrophy Market Size and Trends
- Corneal Endothelial Dystrophy Market Opportunities
- Impact of upcoming Corneal Endothelial Dystrophy Therapies
Corneal Endothelial Dystrophy Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Corneal Endothelial Dystrophy Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Corneal Endothelial Dystrophy Report Assessment
- Current Treatment Practices
- Unmet Needs
- Corneal Endothelial Dystrophy Pipeline Product Profiles
- Corneal Endothelial Dystrophy Market Attractiveness
- Market Drivers and Barriers
Key Questions
Market Insights:
- What was the Corneal Endothelial Dystrophy drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Corneal Endothelial Dystrophy total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Corneal Endothelial Dystrophy market size during the forecast period (2019-2032)?
- At what CAGR, the Corneal Endothelial Dystrophy market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the Corneal Endothelial Dystrophy market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Corneal Endothelial Dystrophy market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of the Corneal Endothelial Dystrophy?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Corneal Endothelial Dystrophy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Corneal Endothelial Dystrophy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Corneal Endothelial Dystrophy?
- Out of all 7MM countries, which country would have the highest prevalent population of Corneal Endothelial Dystrophy during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Corneal Endothelial Dystrophy treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Corneal Endothelial Dystrophy in the USA, Europe, and Japan?
- What are the Corneal Endothelial Dystrophy marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Corneal Endothelial Dystrophy?
- How many therapies are in-development by each company for Corneal Endothelial Dystrophy treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Corneal Endothelial Dystrophy treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Corneal Endothelial Dystrophy therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Corneal Endothelial Dystrophy and their status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Corneal Endothelial Dystrophy?
- What are the global historical and forecasted market of Corneal Endothelial Dystrophy?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Corneal Endothelial Dystrophy market
- To understand the future market competition in the Corneal Endothelial Dystrophy market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Corneal Endothelial Dystrophy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Corneal Endothelial Dystrophy market
- To understand the future market competition in the Corneal Endothelial Dystrophy market
